| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 28 | 2024 | 428 | 10.930 |
Why?
|
| Adenocarcinoma, Follicular | 12 | 2024 | 55 | 6.230 |
Why?
|
| Carcinoma, Papillary | 11 | 2024 | 157 | 4.760 |
Why?
|
| Salivary Gland Neoplasms | 8 | 2024 | 80 | 4.670 |
Why?
|
| Biomarkers, Tumor | 22 | 2024 | 1549 | 4.510 |
Why?
|
| Adenoma | 7 | 2024 | 250 | 3.400 |
Why?
|
| Bone Neoplasms | 5 | 2022 | 321 | 2.740 |
Why?
|
| Immunohistochemistry | 17 | 2024 | 1806 | 2.740 |
Why?
|
| Thyroid Nodule | 5 | 2022 | 62 | 2.640 |
Why?
|
| Soft Tissue Neoplasms | 5 | 2023 | 129 | 2.320 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2024 | 1096 | 2.040 |
Why?
|
| Sarcoma | 4 | 2023 | 217 | 2.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 8 | 2022 | 147 | 2.000 |
Why?
|
| Osteosarcoma | 4 | 2022 | 163 | 2.000 |
Why?
|
| Lymphatic Metastasis | 6 | 2021 | 498 | 2.000 |
Why?
|
| Adenocarcinoma, Clear Cell | 4 | 2023 | 61 | 1.960 |
Why?
|
| Humans | 104 | 2024 | 90640 | 1.440 |
Why?
|
| Parathyroid Neoplasms | 3 | 2021 | 60 | 1.400 |
Why?
|
| Chondrosarcoma | 2 | 2022 | 50 | 1.280 |
Why?
|
| Choristoma | 2 | 2021 | 68 | 1.260 |
Why?
|
| Oropharyngeal Neoplasms | 5 | 2024 | 132 | 1.260 |
Why?
|
| Head and Neck Neoplasms | 6 | 2023 | 1061 | 1.160 |
Why?
|
| Paranasal Sinus Neoplasms | 2 | 2024 | 26 | 1.130 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2018 | 104 | 1.120 |
Why?
|
| Oncogene Proteins | 2 | 2024 | 64 | 1.060 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 2 | 2024 | 15 | 1.060 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2024 | 43 | 1.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2020 | 105 | 1.010 |
Why?
|
| Diagnosis, Differential | 10 | 2021 | 1608 | 0.990 |
Why?
|
| Middle Aged | 36 | 2024 | 26347 | 0.970 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2024 | 13 | 0.960 |
Why?
|
| Larynx | 3 | 2022 | 37 | 0.950 |
Why?
|
| Skull Base Neoplasms | 1 | 2024 | 14 | 0.950 |
Why?
|
| Aged | 31 | 2024 | 19424 | 0.940 |
Why?
|
| Female | 46 | 2024 | 46894 | 0.940 |
Why?
|
| Ear Canal | 1 | 2024 | 16 | 0.940 |
Why?
|
| Ear Neoplasms | 1 | 2024 | 13 | 0.930 |
Why?
|
| Parotid Neoplasms | 2 | 2021 | 18 | 0.930 |
Why?
|
| Parathyroid Glands | 2 | 2022 | 74 | 0.910 |
Why?
|
| Male | 44 | 2024 | 42967 | 0.890 |
Why?
|
| Adult | 34 | 2024 | 26953 | 0.870 |
Why?
|
| Aged, 80 and over | 14 | 2024 | 6816 | 0.840 |
Why?
|
| Glomus Tumor | 1 | 2022 | 9 | 0.820 |
Why?
|
| Thyroid Gland | 5 | 2022 | 281 | 0.810 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2019 | 1362 | 0.800 |
Why?
|
| Oncogene Proteins, Fusion | 7 | 2024 | 133 | 0.790 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2022 | 6 | 0.790 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2021 | 6 | 0.770 |
Why?
|
| Chondroma | 1 | 2021 | 7 | 0.770 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2022 | 45 | 0.750 |
Why?
|
| Carcinoma, Papillary, Follicular | 2 | 2020 | 14 | 0.740 |
Why?
|
| Gene Rearrangement | 2 | 2019 | 177 | 0.740 |
Why?
|
| Cartilage | 2 | 2021 | 117 | 0.740 |
Why?
|
| Melanoma | 2 | 2017 | 474 | 0.730 |
Why?
|
| Mutation | 11 | 2024 | 4183 | 0.720 |
Why?
|
| Neck | 2 | 2021 | 104 | 0.710 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2020 | 31 | 0.680 |
Why?
|
| Telomerase | 1 | 2020 | 67 | 0.680 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2020 | 30 | 0.680 |
Why?
|
| Adenocarcinoma | 3 | 2024 | 1182 | 0.670 |
Why?
|
| Genetic Techniques | 1 | 2020 | 73 | 0.670 |
Why?
|
| Biopsy | 7 | 2023 | 1192 | 0.670 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2023 | 333 | 0.650 |
Why?
|
| Integrin beta3 | 1 | 2019 | 32 | 0.650 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2019 | 17 | 0.650 |
Why?
|
| Young Adult | 15 | 2022 | 6426 | 0.640 |
Why?
|
| Prognosis | 12 | 2022 | 3813 | 0.630 |
Why?
|
| Papillomavirus Infections | 6 | 2024 | 264 | 0.630 |
Why?
|
| Skin Neoplasms | 2 | 2021 | 601 | 0.620 |
Why?
|
| Laryngeal Neoplasms | 2 | 2017 | 89 | 0.620 |
Why?
|
| Bone Cysts, Aneurysmal | 1 | 2018 | 7 | 0.620 |
Why?
|
| Adolescent | 15 | 2022 | 9354 | 0.620 |
Why?
|
| Myxoma | 2 | 2020 | 30 | 0.620 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2018 | 25 | 0.600 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2018 | 66 | 0.600 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 525 | 0.590 |
Why?
|
| Biopsy, Fine-Needle | 5 | 2022 | 107 | 0.580 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 376 | 0.580 |
Why?
|
| MicroRNAs | 1 | 2022 | 561 | 0.580 |
Why?
|
| Mammary Analogue Secretory Carcinoma | 1 | 2017 | 4 | 0.570 |
Why?
|
| Retrospective Studies | 16 | 2022 | 9330 | 0.570 |
Why?
|
| Ubiquitin | 1 | 2018 | 96 | 0.570 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2017 | 14 | 0.560 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2017 | 24 | 0.560 |
Why?
|
| Mandible | 1 | 2018 | 124 | 0.550 |
Why?
|
| Mouth Neoplasms | 3 | 2018 | 199 | 0.540 |
Why?
|
| Multiple Myeloma | 2 | 2017 | 337 | 0.530 |
Why?
|
| Trans-Activators | 1 | 2019 | 443 | 0.530 |
Why?
|
| Trachea | 1 | 2017 | 292 | 0.520 |
Why?
|
| Cell Differentiation | 3 | 2024 | 1553 | 0.510 |
Why?
|
| Parotid Gland | 3 | 2021 | 31 | 0.510 |
Why?
|
| Papillomaviridae | 4 | 2022 | 156 | 0.510 |
Why?
|
| Lung Neoplasms | 4 | 2020 | 2370 | 0.500 |
Why?
|
| Receptor, ErbB-2 | 1 | 2017 | 253 | 0.500 |
Why?
|
| Odontogenic Tumors | 1 | 2015 | 12 | 0.490 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 419 | 0.490 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 349 | 0.490 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2015 | 24 | 0.480 |
Why?
|
| Pleural Neoplasms | 1 | 2017 | 204 | 0.480 |
Why?
|
| Temporal Bone | 1 | 2015 | 69 | 0.470 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2014 | 31 | 0.460 |
Why?
|
| Thoracic Neoplasms | 2 | 2019 | 66 | 0.450 |
Why?
|
| Skin | 1 | 2017 | 590 | 0.440 |
Why?
|
| Pigmentation | 1 | 2014 | 73 | 0.440 |
Why?
|
| Carcinoma | 3 | 2022 | 438 | 0.430 |
Why?
|
| Vocal Cords | 2 | 2022 | 28 | 0.420 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 2525 | 0.410 |
Why?
|
| Idiopathic Interstitial Pneumonias | 1 | 2012 | 28 | 0.410 |
Why?
|
| Thyroidectomy | 4 | 2022 | 171 | 0.400 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2024 | 604 | 0.390 |
Why?
|
| DNA Mutational Analysis | 4 | 2021 | 531 | 0.390 |
Why?
|
| Connective Tissue Diseases | 1 | 2012 | 70 | 0.390 |
Why?
|
| Laryngeal Diseases | 1 | 2011 | 20 | 0.370 |
Why?
|
| Cumulative Trauma Disorders | 1 | 2011 | 19 | 0.370 |
Why?
|
| Lymph Nodes | 3 | 2021 | 553 | 0.360 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 1066 | 0.360 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 473 | 0.360 |
Why?
|
| Disease-Free Survival | 3 | 2024 | 1170 | 0.350 |
Why?
|
| Warts | 1 | 2010 | 12 | 0.340 |
Why?
|
| Agammaglobulinemia | 1 | 2010 | 20 | 0.340 |
Why?
|
| Pneumocephalus | 1 | 2009 | 10 | 0.330 |
Why?
|
| Embolism, Air | 1 | 2009 | 23 | 0.330 |
Why?
|
| Transcription Factors | 3 | 2022 | 1670 | 0.330 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2020 | 355 | 0.310 |
Why?
|
| ras Proteins | 2 | 2020 | 131 | 0.310 |
Why?
|
| Cell Nucleus | 3 | 2024 | 605 | 0.300 |
Why?
|
| Neoplasm Staging | 5 | 2021 | 2019 | 0.290 |
Why?
|
| Hemorrhage | 1 | 2009 | 290 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2008 | 200 | 0.270 |
Why?
|
| Translocation, Genetic | 2 | 2017 | 264 | 0.260 |
Why?
|
| Treatment Outcome | 5 | 2024 | 8379 | 0.240 |
Why?
|
| Mitotic Index | 1 | 2024 | 22 | 0.240 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 1747 | 0.240 |
Why?
|
| Ki-67 Antigen | 1 | 2024 | 67 | 0.240 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2024 | 7 | 0.240 |
Why?
|
| Gene Fusion | 1 | 2024 | 42 | 0.240 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2024 | 60 | 0.230 |
Why?
|
| Survival Rate | 4 | 2016 | 1895 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2022 | 3486 | 0.220 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2009 | 1129 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 2 | 2019 | 570 | 0.210 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2021 | 99 | 0.210 |
Why?
|
| Fatal Outcome | 2 | 2017 | 298 | 0.210 |
Why?
|
| Cell Proliferation | 2 | 2024 | 1695 | 0.210 |
Why?
|
| Frozen Sections | 1 | 2022 | 50 | 0.200 |
Why?
|
| Pathologists | 1 | 2022 | 30 | 0.200 |
Why?
|
| Actinomycosis | 1 | 2022 | 12 | 0.200 |
Why?
|
| Graves Disease | 1 | 2022 | 36 | 0.200 |
Why?
|
| Iodine Radioisotopes | 1 | 2023 | 135 | 0.200 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2021 | 1259 | 0.200 |
Why?
|
| Vocal Cord Paralysis | 1 | 2022 | 27 | 0.200 |
Why?
|
| Fingers | 1 | 2022 | 69 | 0.200 |
Why?
|
| Hyperthyroidism | 1 | 2022 | 76 | 0.200 |
Why?
|
| False Negative Reactions | 2 | 2018 | 63 | 0.200 |
Why?
|
| SOX9 Transcription Factor | 1 | 2022 | 28 | 0.200 |
Why?
|
| Histoplasmosis | 1 | 2022 | 26 | 0.200 |
Why?
|
| Lower Extremity | 1 | 2022 | 89 | 0.190 |
Why?
|
| Language | 1 | 2023 | 157 | 0.190 |
Why?
|
| Parathyroidectomy | 1 | 2022 | 80 | 0.190 |
Why?
|
| Nose Neoplasms | 1 | 2021 | 30 | 0.190 |
Why?
|
| Submandibular Gland Neoplasms | 1 | 2021 | 7 | 0.190 |
Why?
|
| Carcinosarcoma | 1 | 2021 | 23 | 0.190 |
Why?
|
| Submandibular Gland | 1 | 2021 | 17 | 0.190 |
Why?
|
| Drug Monitoring | 1 | 2022 | 118 | 0.180 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2021 | 26 | 0.180 |
Why?
|
| DNA, Viral | 1 | 2022 | 265 | 0.180 |
Why?
|
| Neoadjuvant Therapy | 1 | 2024 | 388 | 0.180 |
Why?
|
| Femur | 1 | 2021 | 112 | 0.180 |
Why?
|
| Teratoma | 1 | 2021 | 52 | 0.180 |
Why?
|
| Parathyroid Hormone | 1 | 2022 | 221 | 0.180 |
Why?
|
| Neoplasms | 3 | 2021 | 3030 | 0.180 |
Why?
|
| Mediastinum | 1 | 2021 | 47 | 0.180 |
Why?
|
| Specimen Handling | 1 | 2021 | 103 | 0.180 |
Why?
|
| Angiofibroma | 1 | 2020 | 4 | 0.180 |
Why?
|
| Vulvar Neoplasms | 1 | 2020 | 19 | 0.180 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2020 | 13 | 0.180 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 83 | 0.180 |
Why?
|
| Polyps | 1 | 2020 | 29 | 0.170 |
Why?
|
| Risk Factors | 4 | 2019 | 5583 | 0.170 |
Why?
|
| Nelson Syndrome | 1 | 2020 | 3 | 0.170 |
Why?
|
| Prolactinoma | 1 | 2020 | 8 | 0.170 |
Why?
|
| Pain | 1 | 2022 | 399 | 0.170 |
Why?
|
| Tongue Neoplasms | 2 | 2018 | 52 | 0.170 |
Why?
|
| Infant | 2 | 2017 | 3184 | 0.160 |
Why?
|
| beta Catenin | 1 | 2021 | 267 | 0.160 |
Why?
|
| Dermatofibrosarcoma | 1 | 2019 | 14 | 0.160 |
Why?
|
| Ultrasonography | 3 | 2019 | 722 | 0.160 |
Why?
|
| Face | 1 | 2020 | 118 | 0.160 |
Why?
|
| Suicidal Ideation | 1 | 2020 | 74 | 0.160 |
Why?
|
| Calciphylaxis | 1 | 2018 | 4 | 0.160 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2019 | 70 | 0.160 |
Why?
|
| Breast Diseases | 2 | 2011 | 101 | 0.160 |
Why?
|
| Vena Cava, Superior | 1 | 2019 | 60 | 0.160 |
Why?
|
| Cytodiagnosis | 1 | 2019 | 46 | 0.160 |
Why?
|
| Blood Platelets | 1 | 2019 | 151 | 0.160 |
Why?
|
| Publication Bias | 1 | 2018 | 13 | 0.160 |
Why?
|
| Epithelial Cells | 1 | 2023 | 693 | 0.160 |
Why?
|
| Histiocytic Necrotizing Lymphadenitis | 1 | 2018 | 2 | 0.150 |
Why?
|
| Maxillary Sinus | 1 | 2018 | 26 | 0.150 |
Why?
|
| Dental Alloys | 1 | 2018 | 5 | 0.150 |
Why?
|
| Orthodontic Appliances | 1 | 2018 | 7 | 0.150 |
Why?
|
| Inclusion Bodies | 1 | 2018 | 34 | 0.150 |
Why?
|
| Pathology | 1 | 2018 | 32 | 0.150 |
Why?
|
| Skull | 1 | 2020 | 257 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 1286 | 0.140 |
Why?
|
| GTP Phosphohydrolases | 1 | 2018 | 75 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 11 | 0.140 |
Why?
|
| Myoepithelioma | 1 | 2017 | 11 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2017 | 23 | 0.140 |
Why?
|
| Plasma Cells | 1 | 2017 | 85 | 0.140 |
Why?
|
| Life Style | 1 | 2018 | 174 | 0.140 |
Why?
|
| Genes, ras | 1 | 2017 | 97 | 0.140 |
Why?
|
| Skin Diseases | 1 | 2018 | 174 | 0.140 |
Why?
|
| Nuclear Proteins | 2 | 2022 | 728 | 0.140 |
Why?
|
| Melanocytes | 1 | 2017 | 57 | 0.140 |
Why?
|
| Receptors, Androgen | 1 | 2017 | 119 | 0.130 |
Why?
|
| Rhabdoid Tumor | 1 | 2016 | 20 | 0.130 |
Why?
|
| Forehead | 1 | 2016 | 15 | 0.130 |
Why?
|
| Receptors, Progesterone | 1 | 2017 | 176 | 0.130 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2016 | 11 | 0.130 |
Why?
|
| Skull Neoplasms | 1 | 2016 | 30 | 0.130 |
Why?
|
| Retinoblastoma | 1 | 2016 | 28 | 0.130 |
Why?
|
| Jaw Cysts | 1 | 2016 | 3 | 0.130 |
Why?
|
| Synovial Cyst | 1 | 2016 | 8 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 961 | 0.130 |
Why?
|
| Ganglion Cysts | 1 | 2016 | 4 | 0.130 |
Why?
|
| Pyrazoles | 1 | 2017 | 151 | 0.130 |
Why?
|
| RNA, Viral | 1 | 2017 | 320 | 0.130 |
Why?
|
| Osteolysis, Essential | 1 | 2015 | 1 | 0.130 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2016 | 95 | 0.130 |
Why?
|
| Temporomandibular Joint Disorders | 1 | 2016 | 21 | 0.130 |
Why?
|
| Obesity | 1 | 2022 | 979 | 0.130 |
Why?
|
| Rare Diseases | 1 | 2016 | 69 | 0.130 |
Why?
|
| Radiology | 1 | 2018 | 204 | 0.130 |
Why?
|
| Transcriptome | 1 | 2020 | 674 | 0.120 |
Why?
|
| Fractals | 1 | 2015 | 42 | 0.120 |
Why?
|
| Receptors, Estrogen | 1 | 2017 | 395 | 0.120 |
Why?
|
| Colonography, Computed Tomographic | 2 | 2006 | 81 | 0.120 |
Why?
|
| Antibodies | 1 | 2017 | 353 | 0.120 |
Why?
|
| Pelvis | 1 | 2015 | 96 | 0.120 |
Why?
|
| Cancer Survivors | 1 | 2016 | 63 | 0.120 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2016 | 81 | 0.120 |
Why?
|
| Pyridines | 1 | 2017 | 303 | 0.120 |
Why?
|
| Cognition | 1 | 2020 | 588 | 0.120 |
Why?
|
| Age Factors | 2 | 2018 | 1871 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 923 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 407 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 283 | 0.120 |
Why?
|
| Cell Dedifferentiation | 1 | 2013 | 8 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 406 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2016 | 240 | 0.110 |
Why?
|
| Child | 3 | 2022 | 7219 | 0.110 |
Why?
|
| Calcium | 1 | 2018 | 1183 | 0.110 |
Why?
|
| Chemoradiotherapy | 3 | 2022 | 304 | 0.110 |
Why?
|
| Ankle | 1 | 2013 | 21 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 1397 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 610 | 0.110 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 478 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 493 | 0.110 |
Why?
|
| Disease Progression | 1 | 2017 | 1486 | 0.100 |
Why?
|
| Carboplatin | 2 | 2024 | 311 | 0.100 |
Why?
|
| Time Factors | 2 | 2019 | 5366 | 0.100 |
Why?
|
| Granular Cell Tumor | 1 | 2011 | 5 | 0.090 |
Why?
|
| Neoplasm Proteins | 2 | 2017 | 538 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2018 | 1232 | 0.090 |
Why?
|
| Histiocytosis, Sinus | 1 | 2011 | 15 | 0.090 |
Why?
|
| Paclitaxel | 2 | 2024 | 484 | 0.090 |
Why?
|
| Appendiceal Neoplasms | 1 | 2011 | 31 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2705 | 0.090 |
Why?
|
| Biomarkers | 2 | 2015 | 1800 | 0.090 |
Why?
|
| Mitochondria, Muscle | 1 | 2010 | 27 | 0.090 |
Why?
|
| Child, Preschool | 2 | 2017 | 3767 | 0.090 |
Why?
|
| Appendicitis | 1 | 2011 | 71 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 2364 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2017 | 1384 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 686 | 0.080 |
Why?
|
| Subarachnoid Space | 1 | 2009 | 17 | 0.080 |
Why?
|
| Cerebral Arteries | 1 | 2009 | 74 | 0.080 |
Why?
|
| Brain Infarction | 1 | 2009 | 23 | 0.080 |
Why?
|
| Siblings | 1 | 2010 | 106 | 0.080 |
Why?
|
| Superoxide Dismutase | 1 | 2010 | 177 | 0.080 |
Why?
|
| Breast | 1 | 2011 | 289 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 2 | 2010 | 370 | 0.080 |
Why?
|
| Syndrome | 1 | 2010 | 452 | 0.080 |
Why?
|
| Genotype | 1 | 2013 | 1855 | 0.080 |
Why?
|
| Bone Marrow Cells | 1 | 2010 | 263 | 0.080 |
Why?
|
| Iliac Vein | 1 | 2008 | 32 | 0.080 |
Why?
|
| Bronchi | 1 | 2009 | 230 | 0.080 |
Why?
|
| Bacterial Infections | 1 | 2010 | 185 | 0.070 |
Why?
|
| Epigastric Arteries | 1 | 2007 | 9 | 0.070 |
Why?
|
| Tissue Preservation | 1 | 2007 | 14 | 0.070 |
Why?
|
| Carcinoma, Small Cell | 1 | 2008 | 133 | 0.070 |
Why?
|
| Lumbar Vertebrae | 1 | 2008 | 152 | 0.070 |
Why?
|
| Rectus Abdominis | 1 | 2007 | 40 | 0.070 |
Why?
|
| Pulmonary Artery | 1 | 2009 | 324 | 0.070 |
Why?
|
| Veins | 1 | 2007 | 95 | 0.070 |
Why?
|
| Vena Cava, Inferior | 1 | 2008 | 148 | 0.070 |
Why?
|
| Lung Diseases | 1 | 2009 | 276 | 0.070 |
Why?
|
| Cathartics | 1 | 2006 | 27 | 0.070 |
Why?
|
| Citric Acid | 1 | 2006 | 46 | 0.070 |
Why?
|
| Dietary Fiber | 1 | 2006 | 44 | 0.070 |
Why?
|
| Ileocecal Valve | 1 | 2006 | 5 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 526 | 0.060 |
Why?
|
| Mammaplasty | 1 | 2007 | 116 | 0.060 |
Why?
|
| Organometallic Compounds | 1 | 2006 | 140 | 0.060 |
Why?
|
| Venous Thrombosis | 1 | 2008 | 260 | 0.060 |
Why?
|
| Oceania | 1 | 2024 | 5 | 0.060 |
Why?
|
| Surgical Flaps | 1 | 2007 | 254 | 0.060 |
Why?
|
| Mesothelioma | 1 | 2008 | 326 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 1462 | 0.060 |
Why?
|
| Brain Ischemia | 1 | 2009 | 399 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 854 | 0.060 |
Why?
|
| Asia | 1 | 2024 | 103 | 0.060 |
Why?
|
| Feces | 1 | 2006 | 335 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 3698 | 0.060 |
Why?
|
| North America | 1 | 2024 | 188 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 2782 | 0.060 |
Why?
|
| Europe | 1 | 2024 | 328 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2022 | 791 | 0.050 |
Why?
|
| Kidney | 1 | 2008 | 1150 | 0.050 |
Why?
|
| Government Agencies | 1 | 2022 | 11 | 0.050 |
Why?
|
| Irritants | 1 | 2022 | 4 | 0.050 |
Why?
|
| Salivary Glands | 1 | 2022 | 18 | 0.050 |
Why?
|
| Lung | 1 | 2009 | 1305 | 0.050 |
Why?
|
| Head | 1 | 2023 | 137 | 0.050 |
Why?
|
| Pharynx | 1 | 2022 | 44 | 0.050 |
Why?
|
| Incidence | 2 | 2018 | 1594 | 0.050 |
Why?
|
| Hoarseness | 1 | 2022 | 11 | 0.050 |
Why?
|
| Necrosis | 1 | 2022 | 211 | 0.050 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 44 | 0.050 |
Why?
|
| Consensus | 1 | 2023 | 371 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2021 | 32 | 0.050 |
Why?
|
| Induction Chemotherapy | 1 | 2022 | 153 | 0.050 |
Why?
|
| Vulva | 1 | 2020 | 23 | 0.040 |
Why?
|
| Hematoxylin | 1 | 2020 | 6 | 0.040 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2020 | 11 | 0.040 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2020 | 80 | 0.040 |
Why?
|
| Sella Turcica | 1 | 2020 | 17 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2022 | 399 | 0.040 |
Why?
|
| Cisplatin | 1 | 2022 | 599 | 0.040 |
Why?
|
| Brain | 1 | 2009 | 2328 | 0.040 |
Why?
|
| Neck Pain | 1 | 2018 | 18 | 0.040 |
Why?
|
| Proteomics | 1 | 2020 | 242 | 0.040 |
Why?
|
| Oral Health | 1 | 2018 | 10 | 0.040 |
Why?
|
| Genomics | 1 | 2024 | 784 | 0.040 |
Why?
|
| Radiography | 2 | 2011 | 809 | 0.040 |
Why?
|
| Suicide | 1 | 2020 | 151 | 0.040 |
Why?
|
| Memory | 1 | 2020 | 221 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2018 | 220 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2022 | 4348 | 0.040 |
Why?
|
| Metals | 1 | 2018 | 99 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2017 | 126 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2019 | 327 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2017 | 313 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 806 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 129 | 0.030 |
Why?
|
| Recurrence | 1 | 2020 | 1162 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2017 | 143 | 0.030 |
Why?
|
| Emotions | 1 | 2020 | 358 | 0.030 |
Why?
|
| False Positive Reactions | 2 | 2006 | 223 | 0.030 |
Why?
|
| Observer Variation | 1 | 2017 | 615 | 0.030 |
Why?
|
| SEER Program | 1 | 2016 | 202 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 275 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2017 | 237 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 841 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 875 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1074 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2338 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 2019 | 0.020 |
Why?
|
| Chicago | 1 | 2016 | 1441 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 2891 | 0.020 |
Why?
|
| Rats, Mutant Strains | 1 | 2010 | 23 | 0.020 |
Why?
|
| Biomimetics | 1 | 2010 | 31 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2016 | 2502 | 0.020 |
Why?
|
| Hemosiderosis | 1 | 2009 | 3 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2010 | 159 | 0.020 |
Why?
|
| Pulmonary Alveolar Proteinosis | 1 | 2009 | 4 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2670 | 0.020 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2010 | 140 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2010 | 349 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2018 | 1068 | 0.020 |
Why?
|
| Alopecia | 1 | 2008 | 34 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 3020 | 0.020 |
Why?
|
| Back Pain | 1 | 2008 | 43 | 0.020 |
Why?
|
| Hematuria | 1 | 2008 | 50 | 0.020 |
Why?
|
| Models, Biological | 1 | 2015 | 1770 | 0.020 |
Why?
|
| Mammography | 1 | 2011 | 468 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2010 | 1242 | 0.020 |
Why?
|
| Microcirculation | 1 | 2007 | 105 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2008 | 142 | 0.020 |
Why?
|
| Intestinal Polyps | 1 | 2006 | 27 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2006 | 152 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 2008 | 263 | 0.020 |
Why?
|
| Mastectomy | 1 | 2007 | 252 | 0.020 |
Why?
|
| United States | 1 | 2018 | 7142 | 0.020 |
Why?
|
| Reoperation | 1 | 2007 | 609 | 0.010 |
Why?
|
| Colonic Polyps | 1 | 2006 | 132 | 0.010 |
Why?
|
| Colonoscopy | 1 | 2006 | 281 | 0.010 |
Why?
|
| Radiographic Image Enhancement | 1 | 2006 | 466 | 0.010 |
Why?
|
| Rats | 1 | 2010 | 4061 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2006 | 879 | 0.010 |
Why?
|
| Apoptosis | 1 | 2010 | 1725 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 2473 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2006 | 263 | 0.010 |
Why?
|
| Colon | 1 | 2006 | 522 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 2409 | 0.010 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2006 | 476 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2006 | 807 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2006 | 572 | 0.010 |
Why?
|
| Animals | 1 | 2010 | 27715 | 0.010 |
Why?
|